Logistics 4.0 in warehousing: a conceptual framework of influencing factors, benefits and barriers

Purpose: In the last decade, the Industry 4.0 paradigm had started to rapidly expand to the logistics domain. However, Logistics 4.0 is still in an early adoption stage: some areas such as warehousing are still exploring its applicability, and the technological implementation of this paradigm can become fuzzy. This paper addresses this gap by examining the relationship among influencing factors, barriers, and benefits of Logistics 4.0 technologies in warehousing contexts. Design/methodology/approach: Starting from a Systematic Literature Review (SLR) approach with 56 examined documents published in scientific journals or conference proceedings, a conceptual framework for Logistics 4.0 in warehousing is proposed. The framework encompasses multiple aspects related to the potential adopter’s decision-making process. Findings: Influencing factors toward adoption, achievable benefits, and possible hurdles or criticalities have been extensively analyzed and structured into a consistent picture. Company’s digital awareness and readiness result in a major influencing factor, whereas barriers and criticalities are mostly technological, safety and security, and economic in nature. Warehousing process optimization is the key benefit identified. Originality/value: This paper addresses a major gap since most of the research has focused on specific facets, or adopted the technology providers’ perspective, whereas little has been explored in warehousing from the adopters’ view. The main novelty and value lie in providing both academics and practitioners with a thorough view of multiple facets to be considered when approaching Logistics 4.0 in logistics facilities

Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients – a pilot study

<p>Abstract</p> <p>Background</p> <p>Mycophenolic acid (MPA) is widely used as part of immunosuppressive regimens following allograft transplantation. The large pharmacokinetic (PK) and pharmacodynamic (PD) variability and narrow therapeutic range of MPA provide a potential for therapeutic drug monitoring. The objective of this pilot study was to investigate the MPA PK and PD relation in combination with belatacept (2^ndgeneration CTLA4-Ig) or cyclosporine (CsA).</p> <p>Methods</p> <p>Seven renal allograft recipients were randomized to either belatacept (n = 4) or cyclosporine (n = 3) based immunosuppression. Samples for MPA PK and PD evaluations were collected predose and at 1, 2 and 13 weeks posttransplant. Plasma concentrations of MPA were determined by HPLC-UV. Activity of inosine monophosphate dehydrogenase (IMPDH) and the expressions of two <it>IMPDH </it>isoforms were measured in CD4+ cells by HPLC-UV and real-time reverse-transcription PCR, respectively. Subsets of T cells were characterized by flow cytometry.</p> <p>Results</p> <p>The MPA exposure tended to be higher among belatacept patients than in CsA patients at week 1 (P = 0.057). Further, MPA concentrations (AUC_{0–9 h}and C₀) increased with time in both groups and were higher at week 13 than at week 2 (P = 0.031, n = 6). In contrast to the postdose reductions of IMPDH activity observed early posttransplant, IMPDH activity within both treatment groups was elevated throughout the dosing interval at week 13. Transient postdose increments were also observed for <it>IMPDH1 </it>expression, starting at week 1. Higher MPA exposure was associated with larger elevations of <it>IMPDH1 </it>(r = 0.81, P = 0.023, n = 7 for MPA and <it>IMPDH1 </it>AUC_{0–9 h}at week 1). The maximum <it>IMPDH1 </it>expression was 52 (13–177)% higher at week 13 compared to week 1 (P = 0.031, n = 6). One patient showed lower MPA exposure with time and did neither display elevations of IMPDH activity nor <it>IMPDH1 </it>expression. No difference was observed in T cell subsets between treatment groups.</p> <p>Conclusion</p> <p>The significant influence of MPA on <it>IMPDH1 </it>expression, possibly mediated through reduced guanine nucleotide levels, could explain the elevations of IMPDH activity within dosing intervals at week 13. The present regulation of IMPDH in CD4+ cells should be considered when interpreting measurements of IMPDH inhibition.</p

Conjugated oligomers with alternating heterocycles from a single monomer:synthesis and demonstration of electroluminescence

International audienceConjugated oligomers based on two different heterocycles are typically prepared by step growth polycondensation cross-coupling methods from two monomers X-Cycle1-X and M-Cycle2-M with no control of the regioselectivity. In this work, we used a new synthetic strategy that involves an extremely chemoselective reaction of a dielectrophilic compound, X1 Cycle1 X2, with a dinucleophilic component, M1-Cycle2-M2, under Stille conditions. The resulting monomers, X1 Cycle1 Cycle2-M2 are di-heterocyclic push pull monomers that still contain a nucleophilic site (boronic acid) and electrophilic site (bromide) and are set up for a controlled polymerization under Suzuki conditions. In this way, two semiconducting oligomers, based on thiophene / benzene and thiophene / pyridine motifs were synthesized. Both oligomers were characterized in terms of their, thermal, electrochemical, absorption, emission and electroluminescence properties

Risk assessment of dioxins, furans, and dioxin-like PCBs in food in Norway - Scientific Opinion of the Panel on Contaminants of the Norwegian Scientific Committee for Food and Environment

publishedVersio

Cyanobakterier og cyanotoksiner i norske drikkevannskilder - (VKM)

publishedVersio

Standalone vertex finding in the ATLAS muon spectrometer

A dedicated reconstruction algorithm to find decay vertices in the ATLAS muon spectrometer is presented. The algorithm searches the region just upstream of or inside the muon spectrometer volume for multi-particle vertices that originate from the decay of particles with long decay paths. The performance of the algorithm is evaluated using both a sample of simulated Higgs boson events, in which the Higgs boson decays to long-lived neutral particles that in turn decay to bbar b final states, and pp collision data at √s = 7 TeV collected with the ATLAS detector at the LHC during 2011